Diabetes and cancer: Looking at the multiligand/RAGE axis

Figure 1 RAGE engagement activates many signaling pathways which are involved in both diabetes-associated vascular complications and tissue damage, and as well as in the tumor microenvironment-associated inflammatory milieu. RAGE: Receptor of advanced glycation end-products.

Figure 2 Schematic depiction of consequences of RAGE activation in both diabetes and cancer. A common focal point is the onset and perpetuation of inflammatory conditions.